109.00 -3.33 (-2.96%)
After hours: 7:59PM EST
|Bid||108.80 x 900|
|Ask||112.69 x 800|
|Day's range||111.18 - 117.30|
|52-week range||28.00 - 131.00|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Earnings date||10 Nov 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||120.44|
Pfizer Inc and BioNTech SE said on Thursday they are testing a third dose of their COVID-19 vaccine to better understand the immune response against new variants of the virus. They are also in talks with regulatory authorities about testing a vaccine modified to protect specifically against the highly transmissible new variant found in South Africa and elsewhere, known as B.1.351, as a second arm of the same study. The companies believe their current two-dose vaccine will work against the South African variant as well as one found in the United Kingdom and elsewhere.
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today they have begun an evaluation of the safety and immunogenicity of a third dose of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) to understand the effect of a booster on immunity against COVID-19 caused by the circulating and potential newly emerging SARS-CoV-2 variants. The study will draw upon participants from the Phase 1 study in the United States who will be offered the opportunity to receive a 30 µg booster of the current vaccine 6 to 12 months after receiving their initial two-dose regimen. The study is part of the Companies’ clinical development strategy to determine the effectiveness of a third dose against evolving variants.
Moderna announces new expansion plans, and a study for its booster shot that targets the South African variant.